While the Foundation has traditionally emphasized research to identify treatment targets and develop therapies for these genetic retinal conditions, its project portfolio has recently expanded to include natural history studies—ProgStar, for people with Stargardt disease, and RUSH2A, for those with USH2A mutations—as well as the global patient registry at www.MyRetinaTracker.org. This evidence concerns the gene USH2A and Stargardt disease.